他汀类药物可降低慢性乙肝患者的肝癌风险

StephenW

Statins reduce liver cancer risk in patients with chronic HBV

Goh MJ, et al. Hepatol. 2019;doi:10.1002/hep.30973.
October 1, 2019

Statin therapy correlated with a reduced risk for hepatocellular carcinoma in patients with chronic hepatitis B, according to results published in Hepatology.

“Recently, there has been emerging interest in the potential therapeutic application of statins as anticancer agents based on preclinical evidence,” Myung Ji Goh, MD, Sungkyunkwan University School of Medicine, South Korea, and colleagues wrote. “The present study demonstrates an association between statin use and reduced risk of HCC development, and provides strong support to the hypothesis that statins can be chemo-preventive agents for the prevention of HCC development in patients with chronic HBV infection.”

The study comprised 713 patients on statin therapy and 7,000 patients not on statin therapy, all of whom had chronic HBV. Patients on statin therapy were older and were less likely to have cirrhosis or elevated HBV DNA levels compared with those not on statin therapy but had higher rates of diabetes and hypertension.

During a median follow-up of 7.2 years, 672 patients not on statin therapy developed HCC compared with 30 patients on statin therapy (P < .001). The 5-year cumulative incidence rates of HCC were 3.3% among patients on statin therapy and 7.9% among those not on statin therapy.

Multivariate analysis showed that statin use correlated independently with a lower risk for HCC development (HR = 0.36; 95% CI, 0.19-0.68). Similarly, risk for HCC was lower in statin users regardless of cirrhosis, diabetes, and elevated HBV DNA or serum cholesterol levels.

Goh and colleagues noted that the study comprised only Korean patients who predominantly present with HBV genotype C. However, based on evidence of anti-cancer effects from statins, they suspect that statins may also exert anti-HBV activity that warrants further investigation. – by Talitha Bennett

Disclosures: The authors report no relevant financial disclosures.

StephenW

他汀类药物可降低慢性乙肝患者的肝癌风险

Goh MJ等。肝脏病。 2019; DOI：10.1002 / hep.30973。
2019年10月1日

根据《肝病学》上发表的结果，他汀类药物疗法与慢性乙型肝炎患者肝细胞癌风险降低相关。

“最近，基于临床前证据，他汀类药物作为抗癌药的潜在治疗应用引起了人们的兴趣，”韩国成均馆大学医学院医学博士Myung Ji Goh和同事写道。 “本研究证明了他汀类药物的使用与降低的HCC发生风险之间的关联，并为以下假设提供了有力的支持：他汀类可以作为化学预防剂预防慢性HBV感染患者的HCC发生。”

该研究包括713例接受他汀类药物治疗的患者和7,000例未接受他汀类药物治疗的患者，所有患者均患有慢性HBV。与未接受他汀类药物治疗的患者相比，接受他汀类药物治疗的患者年龄较大，肝硬化或HBV DNA水平升高的可能性较小，但糖尿病和高血压的发生率较高。

在7.2年的中位随访期间，未接受他汀类药物治疗的672例患者发生了HCC，而接受他汀类药物治疗的30例患者则发生了HCC（P <.001）。接受他汀类药物治疗的患者的5年HCC累积发生率为3.3％，而未接受他汀类药物治疗的患者则为7.9％。

多变量分析表明，他汀类药物的使用与肝癌发生的较低风险相关（HR = 0.36； 95％CI，0.19-0.68）。同样，无论肝硬化，糖尿病，HBV DNA或血清胆固醇水平升高，他汀类药物使用者的HCC风险均较低。

Goh及其同事指出，该研究仅包括主要表现为HBV基因型C的韩国患者。但是，基于他汀类药物具有抗癌作用的证据，他们怀疑他汀类药物也可能具有抗HBV活性，值得进一步研究。 – Talitha Bennett

披露：作者报告没有相关的财务披露。